Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.38 +7.6% TUNG 1.72 +1.8% LGO 1.01 −2.4% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.30 −2.0% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.73 −0.9% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.38 +7.6% TUNG 1.72 +1.8% LGO 1.01 −2.4% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.30 −2.0% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.73 −0.9%
Other Routine +

Vector Science & Therapeutics Agrees to an Option to Invest in LyoGenesis Plus, Securing Long-Term Access to FDA-Registered, cGMP Manufacturing

Vector Science Secures Manufacturing Access Amid Related-Party Scrutiny

By The Northwire Desk — AI Analysis May 13, 2026 · 10:48 PAIN · 0.77 Vector Science and Therapeutics Corp.
Executive Summary
  • Most Recent (May 13, 2026): Vector Science & Therapeutics entered an option agreement to acquire up to a 15% equity interest in LyoGenesis Plus for up to US$1,000,000 over three years. This secures long-term access to FDA-registered, cGMP-compliant manufacturing via MPP Group LLC's facility in Wisconsin.
  • Previous (May 11, 2026): Company entered a three-year development and manufacturing agreement with MPP Group LLC to produce pharmaceutical-grade peptides, avoiding approximately $6 million in capital expenditures. Focus on 22 novel peptide formulations.
  • Earlier (May 1, 2026): Filed provisional patent for a microneedle catheter platform targeting intratumoral drug delivery (pancreatic cancer). Preclinical stage only.
  • Listing (April 24, 2026): Completed reverse takeover and listing on TSX Venture Exchange (Ticker: PAIN). Raised C$2.31M in concurrent financing. Market cap established at ~C$15.3M with ~153M shares outstanding.
Material Impact
  • Strategic Alignment: The May 13 news confirms and solidifies the manufacturing strategy announced on May 11. While securing an equity stake adds long-term security, it is a follow-up to the initial agreement rather than a fundamentally new revenue driver or asset acquisition.
  • Related Party Risk: Chairman Tommy Thompson and CEO Bill Jackson are minority owners in LyoGenesis Plus (less than 50% equity). They recused themselves from the vote, but this transaction is classified as a "Reviewable Transaction" under TSXV Policy 5.3. This introduces governance scrutiny that may dampen immediate market enthusiasm compared to an arm's-length deal.
  • Capital Efficiency: The option allows access to cGMP manufacturing without the full $6 million CapEx previously avoided, preserving cash for R&D. However, the investment ($1M max) is small relative to the current implied valuation given the price appreciation from listing.
  • Market Reaction: Stock price has been flat at $0.77 since May 8 (May 11 and 12 data). The market appears to have priced in the manufacturing agreement, and the equity option news has not yet triggered a breakout in the provided timeframe.
PAIN · Price
Company Overview
  • Company: Vector Science & Therapeutics Corp. (formerly OpenSesame Acquisition Corp.).
  • Flagship Project: Development of novel peptide formulations (e.g., BCP-157, Retatrutide) and a microneedle catheter platform for intratumoral drug delivery.
  • Development Stage: Preclinical/Patent Filing stage. No commercial revenue reported yet.
  • Manufacturing: Access to MPP Group LLC's 35,000 sq. ft. FDA-registered facility in Mequon, Wisconsin via agreement and equity option.
  • Pipeline: 22 novel peptide formulations targeting the $80.8 billion peptide market.
Read the original news release →

More from Vector Science and Therapeutics Corp.

Jun 30, 2026 · 08:55

Vector Science files provisional patent for magnetic transdermal peptide delivery, targeting De Novo FDA pathway amid rapid pipeline expansion.

M&A / Property Jun 22, 2026 · 07:40

From penny-stock SPAC shell to peptide-play: Vector Science bets on sports-medicine branding and cGMP manufacturing to monetize an $80B market.

M&A / Property Jun 12, 2026 · 07:10

Vector Science & Therapeutics Names Dexter Fowler as Chief Athletic Officer for Its Valor Platform

Management Jun 08, 2026 · 07:50

Vector Science & Therapeutics Appoints Darryl Drake Jr. as President of Valor

Management Jun 02, 2026 · 07:45

Vector Science & Therapeutics Corp. Grants Options as Company Advances Growth Strategy

Management May 11, 2026 · 08:50

Vector swaps $6M capex for a cGMP key, unlocking shelf-stable peptides and signaling a manufacturing-first game plan.

Other